Plain-English translation of NCT04943588 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial studied how effective the medications sofosbuvir plus daclatasvir were at treating hepatitis C in the Pakistani population. Researchers tested participants' blood before and after treatment to see if the virus was completely cured, and examined why some people's treatment might not have worked as expected.
Pakistan was rolling out a large national program to treat hepatitis C, but these particular medications had not been thoroughly tested in Pakistani patients before. The trial existed to prove whether this treatment actually worked as well in this population as it did elsewhere, and to understand what might cause treatment to fail.
Participants received hepatitis C testing at the start of the trial and those with the virus received 12 to 24 weeks of treatment with the study medication. All participants had blood samples taken at multiple visits to check whether the virus was completely cleared, and many completed questionnaires about how the disease affected their quality of life and healthcare costs. The trial team retested participants 12 months after treatment to check if they had stayed cured or if reinfection had occurred.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Pakistan
Sponsor
Queen Mary University of London
Collaborators
Aga Khan University, Dow University of Health Sciences
Enrollment target
~25,000 participants
Started
November 2021
Primary completion
January 2026
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in July 2026.